Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.68 |
| ▸ | CA2 | P00918 | 3/20 | 0.68 |
| ▸ | CA4 | P22748 | 3/20 | 0.68 |
| ▸ | CA6 | P23280 | 3/20 | 0.68 |
| ▸ | CA7 | P43166 | 3/20 | 0.68 |
| ▸ | CA9 | Q16790 | 3/20 | 0.68 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | CA12 | O43570 | 2/20 | 0.68 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.68 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 5/20 | 0.65 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19793283 | 0.87 | MAPK1 (0.70) | CA1CA2CA4CA6CA7 | |
| SCHEMBL1777398 | 0.87 | ALDH1A1 (0.70) | CA1CA2CA4CA6CA7 | |
| SCHEMBL3365457 | 0.87 | ALDH1A1 (0.70) | CA1CA2CA4CA6CA7 | |
| SCHEMBL3365627 | 0.87 | ALDH1A1 (0.70) | CA1CA2CA4CA6CA7 | |
| SCHEMBL9031939 | 0.87 | MAPK1 (0.70) | CA1CA2CA4CA6CA7 | |
| SCHEMBL2215736 | 0.86 | ALDH1A1 (0.68) | CA1CA2CA4CA6CA7 | |
| SCHEMBL6265330 | 0.86 | ALDH1A1 (0.70) | CA1CA2CA4CA6CA7 | |
| SCHEMBL6271004 | 0.86 | ALDH1A1 (0.76) | CA1CA2CA4CA6CA7 | |
| SCHEMBL892079 | 0.85 | ALDH1A1 (0.67) | CA1CA2CA4CA6CA7 | |
| SCHEMBL17967147 | 0.85 | ALDH1A1 (0.67) | CA1CA2CA4CA6CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301260-B2 | Pyrrolidine GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-05-28 | — | — | US | disclosed |
| EP-3268360-B1 | LACTAMS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-3268360-B1 | LACTAMS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2019-04-24 | — | — | EP | disclosed |
| US-10112929-B2 | Lactams as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-10-30 | — | — | US | disclosed |
| US-20180044326-A1 | LACTAMS AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMAPANY (US) | 2018-02-15 | — | — | US | disclosed |
| US-20180044326-A1 | LACTAMS AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMAPANY (US) | 2018-02-15 | — | — | US | disclosed |
| US-20180044326-A1 | LACTAMS AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMAPANY (US) | 2018-02-15 | — | — | US | disclosed |
| EP-3268360-A1 | LACTAMS AS INHIBITORS OF ROCK | Bristol-Myers Squibb Company (US) | 2018-01-17 | — | — | EP | disclosed |
| US-20170081282-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2017-03-23 | — | — | US | disclosed |
| EP-3140294-A1 | PYRROLIDINE GPR40 MODULATORS | Bristol-Myers Squibb Company (US) | 2017-03-15 | — | — | EP | disclosed |
| WO-2016144936-A1 | LACTAMS AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-09-15 | — | — | WO | disclosed |
| WO-2016144936-A1 | LACTAMS AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-09-15 | — | — | WO | disclosed |
| WO-2015171757-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-12 | — | — | WO | disclosed |
| US-20110046105-A1 | Heterocycle-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising them and use thereof | SANOFI-AVENTIS (FR) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081282-A1 | PYRROLIDINE GPR40 MODULATORS | GPR55, GPR65, GPR4 | CA1 4603/4885CA2 2113/4885CA4 3259/4885 |
| US-20180044326-A1 | LACTAMS AS INHIBITORS OF ROCK | MYLK, ROCK1, RHOA | CA1 1024/4885CA2 354/4885CA4 926/4885 |
| US-10301260-B2 | Pyrrolidine GPR40 modulators | GPR55, GPR65, GPR4 | CA1 4603/4885CA2 2113/4885CA4 3259/4885 |
| US-20110046105-A1 | Heterocycle-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising them and use thereof | GIPR, DDC, PGC | CA1 4518/4885CA2 2446/4885CA4 2162/4885 |
| US-10112929-B2 | Lactams as inhibitors of rock | MYLK, ROCK1, RHOA | CA1 1137/4885CA2 349/4885CA4 986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.